Physician profile
Tammie L Thompson
NPI 1356445621
$1,681.54
in general payments reported to CMS, 2019-2025
28 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $539 · 2024: $562 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225 · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.50 |
| Education | $457.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $225.13 | 2023-2025 | Enhertu |
| Abbvie INC. | $205.48 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.39 | 2023 | |
| Lilly USA, LLC | $126.51 | 2024 | Retevmo, Jaypirca, Verzenio |
| Novartis Pharmaceuticals Corporation | $102.63 | 2023-2025 | |
| Seagen INC. | $95.00 | 2024 | |
| Janssen Biotech, INC. | $90.41 | 2025 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $87.89 | 2023-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $77.10 | 2024-2025 | Fruzaqla, Alunbrig |
| Pfizer INC. | $72.88 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.45 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pharmacosmos Therapeutics INC. | $54.51 | 2023-2025 | Monoferric |
| Astellas Pharma US INC | $51.31 | 2023-2025 | Xtandi, Vyloy |
| Celgene Corporation | $34.51 | 2023-2024 | Reblozyl |
| Genentech USA, INC. | $26.69 | 2025 | Polivy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25.00 | 2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $21.10 | 2024 | |
| Tempus Ai, INC | $20.25 | 2024 | |
| Gilead Sciences, INC. | $19.45 | 2024 | |
| Emd Serono, INC. | $18.89 | 2025 | |
| Genzyme Corporation | $17.52 | 2025 | |
| Coherus Oncology, INC. | $17.04 | 2023 | |
| Eisai INC. | $16.09 | 2025 | |
| Taiho Oncology, INC. | $15.77 | 2023 | |
| Deciphera Pharmaceuticals INC. | $15.68 | 2023 | Qinlock |
| Alexion Pharmaceuticals, INC. | $15.38 | 2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $14.41 | 2024 | Rezlidhia, Tavalisse |
| G1 Therapeutics, INC. | $14.07 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammie Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.